Literature DB >> 23050812

Thymosin α1 as a stimulatory agent of innate cell-mediated immune response.

Annalucia Serafino1, Pasquale Pierimarchi, Francesca Pica, Federica Andreola, Roberta Gaziano, Noemi Moroni, Manuela Zonfrillo, Paola Sinibaldi-Vallebona, Enrico Garaci.   

Abstract

The innate immune response and its cellular effectors-peripheral blood mononuclear cells and differentiated macrophages-play a crucial role in detection and elimination of pathogenic microorganisms. Chemotherapy and some immunosuppressive drugs used after organ transplantation and for treatment of autoimmune diseases have, as main side effect, bone marrow suppression, which can lead to a reduced response of the innate immune system. Hence, many immune-depressed patients have a higher risk of developing bacterial and invasive fungal infections compared with immune-competent individuals. Thymosin α1 (Tα1) immunomodulatory activity on effector cells of the innate immunity has been extensively described, even if its mechanism of action is not completely understood. Here, we report some of the main knowledge on this topic, focusing on our in vitro and in vivo work in progress that reinforce the validity of Tα1 as a stimulatory agent for detection and elimination of pathogens by differentiated macrophages and for restoring immune parameters after chemotherapy-induced myelosuppression.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23050812     DOI: 10.1111/j.1749-6632.2012.06707.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases.

Authors:  F Pica; M S Chimenti; R Gaziano; C Buè; I A Casalinuovo; P Triggianese; P Conigliaro; D Di Carlo; V Cordero; G Adorno; A Volpi; R Perricone; E Garaci
Journal:  Clin Exp Immunol       Date:  2016-08-01       Impact factor: 4.330

2.  Proteomic Signatures of Thymomas.

Authors:  Linan Wang; Owen E Branson; Konstantin Shilo; Charles L Hitchcock; Michael A Freitas
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

3.  Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.

Authors:  Chao He; Wei Peng; Chuan Li; Tian-Fu Wen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

4.  Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience.

Authors:  Lin Zhou; Li-Chao Pan; Yong-Gen Zheng; Guo-Sheng Du; Xiao-Qian Fu; Zhi-Dong Zhu; Ji-Yong Song; Zhi-Jia Liu; Xiang-Zheng Su; Wen Chen; De-Hua Zheng; Long-Long Suo; Shao-Zhen Yang
Journal:  Oncol Lett       Date:  2018-07-27       Impact factor: 2.967

Review 5.  Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application.

Authors:  Martina Severa; Jing Zhang; Elena Giacomini; Fabiana Rizzo; Marilena Paola Etna; Melania Cruciani; Enrico Garaci; Michael Chopp; Eliana Marina Coccia
Journal:  Mult Scler Relat Disord       Date:  2018-10-02       Impact factor: 4.339

Review 6.  Role of circulating lymphocytes in patients with sepsis.

Authors:  Raul de Pablo; Jorge Monserrat; Alfredo Prieto; Melchor Alvarez-Mon
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

7.  Immunotherapy - a potential new way forward in the treatment of sepsis.

Authors:  Didier Payen; Guillaume Monneret; Richard Hotchkiss
Journal:  Crit Care       Date:  2013-02-20       Impact factor: 9.097

Review 8.  A Review of GM-CSF Therapy in Sepsis.

Authors:  Brittany Mathias; Benjamin E Szpila; Frederick A Moore; Philip A Efron; Lyle L Moldawer
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  Reduction of FoxP3+ Tregs by an immunosuppressive protocol of rapamycin plus Thymalfasin and Huaier extract predicts positive survival benefits in a rat model of hepatocellular carcinoma.

Authors:  Lin Zhou; Li-Chao Pan; Yong-Gen Zheng; Xin-Xue Zhang; Zhi-Jia Liu; Xuan Meng; Hai-Da Shi; Guo-Sheng Du; Qiang He
Journal:  Ann Transl Med       Date:  2020-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.